Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy.
about
Anti-vascular endothelial growth factor for proliferative diabetic retinopathyAnti-vascular endothelial growth factor for proliferative diabetic retinopathyAnti-VEGF Therapy and the Retina: An UpdateThe angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathyProliferative diabetic retinopathy: predictive and preventive measures at hypoxia induced retinal changes.Diabetic retinopathy: an updateGenetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression.Application of intravitreal bevacizumab for circumscribed choroidal hemangioma.Increased vitreous shedding of microparticles in proliferative diabetic retinopathy stimulates endothelial proliferationProlonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels.Batch-related sterile endophthalmitis following intravitreal injection of bevacizumab.Neovascular glaucomaIntravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.Retro-mode imaging of fibrovascular membrane in proliferative diabetic retinopathy after intravitreal bevacizumab injectionAnti-VEGF Agents for Ocular Angiogenesis and Vascular PermeabilityExploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trialOutcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective AnalysisNeurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab TreatmentIntravitreal bevacizumab for choroidal metastasis of lung carcinoma; a case report.Sustained intraocular VEGF neutralization results in retinal neurodegeneration in the Ins2(Akita) diabetic mouseStrategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice.Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications.Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy.Bevacizumab as an adjunct to vitreoretinal surgery for diabetic retinopathy in East Africa.Diabetic Retinopathy Clinical Practice Guidelines: Customized for Iranian Population.Triamcinolone and bevacizumab as adjunctive therapies to panretinal photocoagulation for proliferative diabetic retinopathyIntravitreal bevacizumab: an analysis of the evidence.Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats.Characteristics of Macular Edema in Behcet Disease after Intravitreal Bevacizumab Injection.Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1.Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis.From pathobiology to the targeting of pericytes for the treatment of diabetic retinopathy25G compared with 20G vitrectomy under Resight non-contact wide-angle lenses for Terson syndrome.Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization.Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization.Retinal microangiopathy in a mouse model of inducible mural cell loss.Descending doses of intravitreal bevacizumab for the regression of diabetic neovascularization.APOPTOSIS AND ANGIOFIBROSIS IN DIABETIC TRACTIONAL MEMBRANES AFTER VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION: Results of a Prospective Trial. Report No. 2.
P2860
Q24187858-495F85EA-D4DD-4EC2-8B02-BFD7CC01EECFQ24236189-2E091FCB-5965-46D0-A87D-C94318705B74Q26784605-0FAEE36A-234F-4F7D-A201-17B44C813060Q30845192-15AEF939-9F45-4273-9F88-0FEC28ACE607Q31107603-1D66DC40-6217-4162-A084-DB99688D2264Q33328784-DA0C9A5F-D048-44DB-8698-B91BA7A44EE5Q33443692-7264C329-59EA-43A8-8028-2983F09AA4D8Q33476808-C31B3D2C-9A17-46ED-937A-18903F9A8C49Q33518352-B7050F2D-F0FD-4755-85CF-99B2CA464066Q33584304-FC26C399-A940-4B8B-9B8C-996F8CBB7226Q33780704-13DD38EF-2FC3-47EE-A16B-F8D5DB3C9012Q33855412-4AC8E078-F49E-44ED-9DC3-A1150F700170Q33902419-5187FFE3-27FA-4312-9FC6-0EEC78B23272Q33949871-6BF7D521-6269-4034-AC12-0DDD72752605Q33961347-8BEEE3D3-58B6-4B03-AA92-AC84FF86FA34Q34088274-E5B47769-F9D3-481F-90EF-82921E5126E8Q34170485-2E6D5AA1-98A3-428D-B327-28CFCFFFAD30Q35553854-41EE0925-B85E-4A53-8C9A-47CC688EB410Q35905482-A7326170-9D91-4147-9524-41760E5A3D68Q36052223-00CD4E4C-ED86-4C17-87CD-366D6546A0E0Q36376302-6AE05C86-B913-4AA1-AC53-2F1A75712F80Q36904857-98D1750D-CEA9-457D-BBF2-90BA30739F9FQ37058905-E5E343F1-76F6-4E20-9BFA-3D7259278E36Q37084522-DB9854FA-B523-4B4F-850B-CEE2602129A4Q37317228-9B536C3B-BA66-4A8F-832A-480C0DB16DC9Q37477129-14382B2F-DBF5-4A92-B845-19EAE92D15C6Q37550878-032DB233-4139-4848-B3BD-78BD9C8EEEB7Q37577410-0C7AFC3D-7C6F-4BC3-95B1-52E4F973B643Q37627442-7940EAD1-1DA6-4168-BF5B-F5E442925F57Q37629986-48F65A56-B40C-4806-895E-EEB21922EE51Q37684328-03DD3298-AC6A-4CEF-9C04-48D5532E64CEQ37700035-D595A8CD-6F37-462F-B98A-D8D7E6B822B2Q38192060-87F0B12E-9D33-45BF-8D1F-694755CB768DQ38332124-18345009-5935-46F2-B89B-E6987C766727Q38623607-8A00CAFB-28D9-41E2-979C-55B0BCF31686Q39023803-83EC4560-CC72-40C2-BC22-62885EBA2299Q39987928-ECEDDA3E-8018-42FD-B81F-B226B18CA27EQ41816335-8722206C-D6BE-4C82-8391-535647EBC6A4Q46167343-DD33E2F3-CC21-419C-8AFF-9328058B671BQ46387723-6B24EC17-7B4F-4266-ABCF-CE8867A4CF9A
P2860
Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Intravitreal injection of beva ...... ferative diabetic retinopathy.
@ast
Intravitreal injection of beva ...... ferative diabetic retinopathy.
@en
type
label
Intravitreal injection of beva ...... ferative diabetic retinopathy.
@ast
Intravitreal injection of beva ...... ferative diabetic retinopathy.
@en
prefLabel
Intravitreal injection of beva ...... ferative diabetic retinopathy.
@ast
Intravitreal injection of beva ...... ferative diabetic retinopathy.
@en
P2093
P1476
Intravitreal injection of beva ...... ferative diabetic retinopathy.
@en
P2093
John O Mason
Milton F White
Peter A Nixon
P304
P356
10.1016/J.AJO.2006.04.058
P407
P577
2006-10-01T00:00:00Z